First case of allergy to nivolumab

J Allergy Clin Immunol Pract. 2017 Jul-Aug;5(4):1140-1141. doi: 10.1016/j.jaip.2017.01.015. Epub 2017 Mar 9.

Authors

Mercedes Sáenz de Santa María García¹, Blanca Noguerado-Mellado², Patricia Rojas-Pérez-Ezquerra², Alicia Prieto-García², Borja Bartolomé-Zavala³, Pilar Tornero²

Affiliations

¹ Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain. Electronic address: mercedessaenzgarcia@gmail.com.
² Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain; Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain.
³ Research and Development Department, BIAL-Arístegui, Bilbao, Spain.

PMID: 28284782
DOI: 10.1016/j.jaip.2017.01.015

No abstract available

Publication types

Letter

MeSH terms

Administration, Intravenous
Allergens / therapeutic use
Angioedema
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Carcinoma, Hepatocellular / complications
Carcinoma, Hepatocellular / diagnosis*
Carcinoma, Hepatocellular / drug therapy
Desensitization, Immunologic / methods*
Drug Hypersensitivity / diagnosis*
Drug Hypersensitivity / etiology
Drug-Related Side Effects and Adverse Reactions / diagnosis*
Female
Humans
Immune Tolerance
Immunoglobulin E / metabolism
Liver Neoplasms / complications
Liver Neoplasms / diagnosis*
Liver Neoplasms / drug therapy
Middle Aged
Nivolumab / adverse effects*
Nivolumab / therapeutic use
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Remission Induction
Skin Tests
Urticaria
Withholding Treatment

Substances

Allergens
Antineoplastic Agents
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab
Immunoglobulin E